Scott Akamine compensation by year
Cerevel Therapeutics Summary Compensation Table · the one fiscal year held| Component | FY2021 |
|---|---|
| Salary | $260,536 |
| Bonus | $50,000 |
| Stock awards | $0 |
| Option awards | $2,749,997 |
| Non-equity incentive | $118,907 |
| Pension and deferred compensation | $0 |
| All other | $15,300 |
| Total | $3,194,740 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cerevel Therapeutics Holdings, Inc. DEF 14A filed April 28, 2022, accession 0001193125-22-127554, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Cerevel Therapeutics Holdings, Inc. filed document, accession 0001193125-22-127554. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2022.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 281,762 | — | $13.17 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Cerevel Therapeutics Holdings, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
15 Form 4 lines since the FY2021 proxy (filed April 28, 2022)current to 2026-11-20 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2024-08-01 | Disposition to the issuer derivative | — | 59,171 | $0.00 | 0 |
| 2024-08-01 | Disposition to the issuer | — | 7,527 | — | 0 |
| 2024-08-01 | Disposition to the issuer derivative | — | 367,126 | — | 0 |
| 2024-01-19 | Grant or award derivative | — | 59,171 | $0.00 | 59,171 |
| 2023-12-20 | Sale | — | 7,072 | $41.42 | 7,237 |
| 2023-12-19 | Exercise or conversion | — | 13,796 | — | 14,309 |
| 2023-12-19 | Exercise or conversion derivative | — | 13,796 | $0.00 | 0 |
| 2023-12-07 | Exercise or conversion derivative | 10b5-1 | 10,000 | $0.00 | 254,262 |
The 8 most recent of 15 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Cerevel Therapeutics’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| N. Anthony Coles | Chairperson and Chief Executive Officer (1) | $8,108,335 |
| Abraham Ceesay | President | $5,276,631 |
| Kathy Yi | Former Chief Financial Officer | $3,501,169 |
| Raymond Sanchez | Chief Medical Officer | $3,416,287 |
| Scott Akamine · this page | Chief Legal Officer and Corporate Secretary | $3,194,740 |
| John Renger | Chief Scientific Officer | $3,093,750 |
| Mark Bodenrader | Interim Chief Financial Officer, Vice President, Finance and Chief Accounting Officer | $1,312,994 |
The full Cerevel Therapeutics compensation record
free company briefThis page is one person within Cerevel Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Cerevel Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cerevel Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.